Listed

Macrogenics Inc: Form 10-Q for the period ended Sep 30, 2022

Filed with the SEC on Nov 3, 2022 and accepted by EDGAR at Nov 3, 2022, 16:03 ET.

Share

Management's discussion and analysis

As filed, 32,045 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with U.S. generally accepted accounting principles (GAAP), for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Overview

We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators. These product candidates include multiple immuno-oncology programs, some of which were created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We only began generating revenues from the sale of products in 2021. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts. Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of September 30, 2022, combined with the $60.0 million received from Gilead Sciences, Inc. (Gilead) under the option and collaboration agreement executed in October 2022, anticipated and potential collaboration payments, product revenues and savings from the execution of our corporate restructuring plan announced in August 2022, should enable us to fund our operations into mid-2024. Our expected funding requirements reflect anticipated expenditures related to the planned Phase 2 portion of the MGC018 clinical trial in metastatic castration-resistant prostate cancer (TAMARACK study), as well as our other clinical and preclinical studies currently ongoing.

Through September 30, 2022, we had an accumulated deficit of $1.1 billion. We expect that over the next several years this deficit will increase as we continue to incur research and development expense in connection with our ongoing preclinical and clinical studies.

COVID-19 Pandemic

The COVID-19 pandemic, including the resulting adverse macroeconomic conditions, has negatively impacted the global economy, created significant financial market volatility, disrupted global supply chains, and resulted in a significant number of infections and deaths worldwide. In addition, several national, state and local governments have placed restrictions on people from gathering in groups or interacting within a certain physical distance.

To date, although there has been some negative impact on our business and operations, including, for example, slowed clinical trial enrollment, we have been able to mitigate against more severe impacts of the COVID-19 pandemic on our business and operations. However, the COVID-19 pandemic could have a more significant negative impact on our business in the future depending on the depth of the effects and the duration of the crisis. In response to the COVID-19 pandemic, we have been focused on keeping our employees safe, continuing patients on trials, and maintaining our manufacturing capabilities and research efforts. The COVID-19 pandemic and its variants continue to evolve and we continue to monitor our business very closely to try and mitigate any potential impacts. We expect the pandemic to continue to have some near-term impact on the initiation of new studies and on clinical trial enrollment. Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize the product candidates in our pipeline. We are classified as a government contractor and were required to comply with Executive Order 14042, which the federal government has indicated it is not currently enforcing. Should the federal government reinstate a vaccination requirement for contractors, we may be required to implement an additional company-wide vaccination requirement for all employees, with certain exceptions. To date, we do not believe our 2021 vaccination requirement resulted in other than minimal workforce attrition nor did it result in material difficulty securing labor needs. If we reinstitute a vaccination or vaccination booster requirement, and associated attrition is significant, our business could be adversely affected.

Notwithstanding the foregoing, we cannot precisely predict the impact that the COVID-19 pandemic will have in the future due to numerous uncertainties, including the severity, duration and resurgences of the disease and new variants, actions that may be taken by governmental authorities, the impact to the business of potential variations or disruptions in our supply chain, and other factors identified in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021. Given these uncertainties, the COVID-19 pandemic could disrupt the business of certain of our collaborators and impact our business operations and our ability to execute on our associated business strategies and initiatives, and adversely impact our consolidated results of operations and/or our financial condition in the future. We will continue to closely monitor and evaluate the nature and extent of the impact of the COVID-19 pandemic to our business, consolidated results of operations, and financial condition.

Collaborations

Our approach is to develop product candidates either by ourselves or in collaboration with partners. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:

  • Incyte. In 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. Incyte paid us an upfront payment of $150.0 million under the terms of the agreement. In July 2021, Incyte announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal. Incyte’s announcement indicated that the FDA determined that additional data were needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte was reviewing the CRL and would discuss next steps with the FDA. Incyte subsequently withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies beyond squamous cell carcinoma of the anal canal, including in patients with MSI-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline. In April 2022, we and Incyte executed an amendment to the Incyte License Agreement to add a milestone for U.S. approval of retifanlimab in a specific indication and to exclude certain other regulatory and development achievements with retifanlimab in this same indication from the milestone events of the Incyte License Agreement. In July 2022, we and Incyte further amended the Incyte License Agreement to reflect changes related to the payment of certain milestones and we received $30.0 million in milestone payments from Incyte.

Under the terms of the Incyte License Agreement, as amended, Incyte leads global development of retifanlimab. Assuming successful development and commercialization of retifanlimab by Incyte, we could receive total development and regulatory milestones of up to approximately $435.0 million and up to $330.0 million in commercial milestones. We received $100.0 million of the total development milestones through September 30, 2022. If retifanlimab is approved and commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte’s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement).

In January 2022, we entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of our manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, we received an upfront payment of $10.0 million and are eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4 million. We will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, we and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1 million.

  • Zai Lab. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab’s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development in its territory. Zai Lab has informed us that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.

Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million. Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones, of which we have already earned $9.0 million. In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab’s territory, mid-teens for net sales of tebotelimab in Zai Lab’s territory and 10% for net sales of the TRIDENT molecule in Zai Lab’s territory, which may be subject to adjustment in specified circumstances.

In 2019, we entered into two agreements under which we are to perform manufacturing services for Zai Lab’s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).

In June 2021, we entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates our DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by us. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while we receive commercial rights in all other territories. Zai Lab also obtained exclusive, global licenses from us to develop, manufacture and commercialize two additional molecules (license-only programs). Zai Lab granted us a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to us. In August 2022, we and Zai Lab agreed to discontinue research and development of the Lead Program.

Under the terms of the 2021 Zai Lab Agreement, the Lead Program included joint research and development services by both us and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with us to perform research and development services in the future.

In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, we and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab paid us approximately $30.0 million to purchase 958,467 newly issued shares of our common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date.

Assuming successful development and commercialization of the remaining Programs under the 2021 Zai Lab Agreement, we could receive up to $1.3 billion in development, regulatory and commercial milestones. In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-single digits to low double digit teens on annual net sales of products in Zai Lab's territory, subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, we may also receive reimbursements from Zai Lab for certain research and development costs incurred by us.

  • I-Mab Biopharma. In 2019, we entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates our proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by us. In August 2022, I-Mab notified us of its intention to terminate the I-Mab License Agreement effective February 25, 2023.

Under the terms of the agreement, I-Mab paid us an upfront payment of $15.0 million and $5.0 million in milestone revenue has been earned from the inception of the I-Mab License Agreement through September 30, 2022.

In October 2021, we entered into an agreement under which we are to perform development and manufacturing services for I-Mab’s clinical needs of enoblituzumab.

  • Janssen. In December 2020, we entered into a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. (Janssen). The research collaboration will incorporate our proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the agreement, Janssen paid us an upfront payment of $20.0 million and will be responsible for funding all expenses. We will also be eligible to receive up to $312.0 million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales.
  • Gilead. On October 14, 2022, we and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using our DART platform, and up to two additional bispecific research programs. The agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). As part of the Gilead Agreement, Gilead paid us an upfront payment of $60.0 million and we will be eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones. We will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products resulting from two research programs.

Critical Accounting Estimates

Our critical accounting estimates are policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. A summary of our critical accounting estimates is presented in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes with respect to our critical accounting estimates during the nine months ended September 30, 2022.

Results of Operations

Revenue

The following represents a comparison of our revenue for the three and nine months ended September 30, 2022 and 2021 (dollars in millions):

Three Months Ended September 30, 2022 2021 Change% Nine Months Ended September 30, 2022 2021 Change%
Collaborative and other agreements $35.7 $12.0 $23.7 198% $59.6 $54.3 $5.3 10%
Product sales, net 4.4 3.6 0.8 22% 12.6 7.7 4.9 64%
Contract manufacturing 1.1 — 1.1 N/A 5.1 — 5.1 N/A
Government agreements 0.5 0.1 0.4 400% 1.5 1.3 0.2 15%
Total revenue $41.7 $15.7 $26.0 166% $78.8 $63.3 $15.5 24%

22

The increase in revenue of $26.0 million for the three months ended September 30, 2022 compared to the three months ended September 30, 2021 was primarily due to:

  • recognition of $30.0 million in milestone payments under the Incyte License Agreement during the three months ended September 30, 2022; and
  • $1.1 million recognized under the Incyte Manufacturing and Clinical Supply Agreement.

These increases were partially offset by:

  • a decrease of $1.6 million in revenue recognized under the I-Mab License Agreement;
  • a decrease of $1.4 million in revenue recognized under the Incyte Commercial Supply Agreement due to timing of manufacturing activities; and
  • a decrease of $1.9 million in revenue recognized under the 2021 Zai Lab Agreement.

The increase in revenue of $15.5 million for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 was primarily due to:

  • an increase of $15.0 million in development milestones recognized under the Incyte License Agreement during the nine months ended September 30, 2022;
  • recognition of a $4.5 million milestone (after netting value-added tax withholding) under the 2018 Zai Lab Agreement during the nine months ended September 30, 2022;
  • an increase of $4.9 million in net product revenue from sales of MARGENZA; and
  • $5.1 million recognized under the Incyte Manufacturing and Clinical Supply Agreement.

These increases were partially offset by:

  • a decrease of $7.0 million in revenue recognized under the Incyte Commercial Supply Agreement due to timing of manufacturing activities;
  • a decrease of $3.4 million in revenue recognized under the I-Mab License Agreement;
  • a decrease of $1.9 million in revenue recognized under the Zai Lab Clinical Supply Agreements; and
  • a decrease of $1.3 million in revenue recognized under the 2021 Zai Lab Agreement.

Revenue from collaborative and other agreements may vary substantially from period to period depending on the progress made by our collaborators with their product candidates and the timing of milestones achieved under current agreements, and whether we enter into additional collaboration agreements.

Cost of Product Sales

Cost of product sales for all periods presented consists primarily of reserves for unsaleable externally-manufactured inventory, as well as product royalties and fill finish costs. Product sold during these periods consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA, which favorably impacted our gross margin. We expect cost of product sales to continue to be positively impacted as we sell through this drug product.

Cost of Manufacturing Services

Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain Incyte bulk drug substance under the Incyte Manufacturing and Clinical Supply Agreement. We entered into this agreement in January 2022, therefore there are no such costs during the three and nine months ended September 30, 2021.

Research and Development Expense

The following represents a comparison of our research and development expense for the three and nine months ended September 30, 2022 and 2021 (dollars in millions):

Three Months Ended September 30, 2022 2021 Change% Nine Months Ended September 30, 2022 2021 Change%
MGC018 $10.1 $6.7 $3.4 51% $37.6 $21.4 $16.2 76%
Margetuximab 6.9 7.1 (0.2) (3)% 22.6 29.2 (6.6) (23)%
Lorigerlimab 4.9 2.7 2.2 81% 14.6 8.5 6.1 72%
Enoblituzumab 3.7 4.3 (0.6) (14)% 12.5 12.5 — —%
MGD024 2.1 — 2.1 N/A 6.1 2.4 3.7 154%
Tebotelimab 1.9 4.7 (2.8) (60)% 9.3 15.4 (6.1) (40)%
DART molecules under HIV government contract 1.8 0.8 1.0 125% 3.6 3.5 0.1 3%
Flotetuzumab 1.5 5.9 (4.4) (75)% 10.8 23.6 (12.8) (54)%
IMGC936 1.4 2.4 (1.0) (42)% 6.2 4.5 1.7 38%
Retifanlimab 0.2 5.2 (5.0) (96)% 1.9 14.1 (12.2) (87)%
Other programs (a) 13.7 10.0 3.7 37% 36.2 23.6 12.6 53%
Total research and development expense $48.2 $49.8 $(1.6) (3)% $161.4 $158.7 $2.7 2%

(a) Includes research and discovery projects, as well as early preclinical and terminated molecules.

Our research and development expense for the three months ended September 30, 2022 decreased by $1.6 million compared to the three months ended September 30, 2021 primarily due to:

  • decreased retifanlimab manufacturing costs related to the Incyte Commercial Supply Agreement;
  • decreased development, manufacturing and clinical trial costs related to flotetuzumab (due to discontinuance of our company-sponsored trial); and
  • decreased development, manufacturing and clinical trial costs related to tebotelimab.

These decreases were partially offset by:

  • increased development, manufacturing and clinical trial costs related to MGC018;
  • increased expenses related to discovery projects and preclinical molecules;
  • increased clinical trial enrollment costs related to lorigerlimab; and
  • clinical trial costs related to initiation of a Phase 1 trial of MGD024 during the three months ended September 30, 2022.

Our research and development expense for the nine months ended September 30, 2022 increased by $2.7 million compared to the nine months ended September 30, 2021 primarily due to:

  • increased development, manufacturing and clinical trial costs related to MGC018;
  • increased development of discovery projects and preclinical molecules;
  • increased clinical trial enrollment costs related to lorigerlimab; and
  • clinical trial costs related to initiation of a Phase 1 trial of MGD024.

These increases were partially offset by:

  • decreased development, manufacturing and clinical trial costs related to flotetuzumab (due to discontinuance of our company-sponsored trial);
  • decreased retifanlimab manufacturing costs related to the Incyte Commercial Supply Agreement;
  • decreased development, manufacturing and clinical trial costs related to tebotelimab; and
  • decreased margetuximab manufacturing costs related to the Zai Lab Clinical Supply Agreement.

There are uncertainties associated with our research and development expenses for future quarters which are impacted by multiple variables, including timing of wind down activities for recently closed studies and current and expected expenditures associated with our Phase 2/3 MGC018 TAMARACK study.

Selling, General and Administrative Expense

Selling, general and administrative expenses decreased by $1.8 million for the three months ended September 30, 2022 compared to the three months ended September 30, 2021 and by $2.2 million for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 primarily due to decreased selling costs for MARGENZA, which launched in March 2021, as well as decreased consulting expenses.

Liquidity and Capital Resources

Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use. Our future success is dependent on our ability to identify and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital, and accordingly, our ability to execute our future operating plans.

As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases. Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization. Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of September 30, 2022, combined with $60.0 million subsequently received from Gilead, anticipated and potential collaboration payments, product revenues and savings from the execution of our corporate restructuring plan, should enable us to fund our operations into mid-2024. Our expected funding requirements reflect anticipated expenditures related to the planned Phase 2 portion of the MGC018 TAMARACK study, as well as our other clinical and nonclinical studies currently ongoing.

Material Cash Requirements

During the nine months ended September 30, 2022, there were no significant changes to our material cash requirements, including contractual and other obligations, as presented in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

Cash Flows

The following table represents a summary of our cash flows for the nine months ended September 30, 2022 and 2021:

(dollars in millions)

Net cash provided by (used in): Nine Months Ended September 30, 2022 2021
Operating activities $(116.3) $(89.5)
Investing activities 76.5 (23.1)
Financing activities 0.3 122.0
Net change in cash and cash equivalents $(39.5) $9.4

Operating Activities

Net cash used in operating activities consists of our net loss adjusted for non-cash items such as depreciation and amortization expense and stock-based compensation and changes in working capital. Net cash used in operating activities for the nine months ended September 30, 2022 benefited from the $30.0 million in milestones received from Incyte under the Incyte License Agreement and $4.5 million (after netting value-added tax withholding) in milestones received under the 2018 Zai Lab Agreement. Net cash used in operating activities for the nine months ended September 30, 2021 benefited from the $25.0 million upfront payment under the 2021 Zai Lab Agreement, the $10.4 million premium over the share price under the Stock Purchase Agreement with Zai Lab, and the $15.0 million milestone payments received under the Incyte License Agreement.

Investing Activities

Net cash provided by investing activities during the nine months ended September 30, 2022 is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities. Net cash used in investing activities during the nine months ended September 30, 2021 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.

Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2021 includes net cash proceeds from our securities offerings of approximately $117.8 million.

Market risk

As filed, 203 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Under SEC rules and regulations, because we are considered to be a “smaller reporting company," we are not required to provide the information required by this item in this Quarterly Report on Form 10-Q.

Controls and procedures

As filed, 1,325 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2022. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of September 30, 2022, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.

Changes in Internal Control

There were no changes in our internal control over financial reporting during the three months ended September 30, 2022 that materially affected, or are reasonably likely to materially effect, our internal control over financial reporting.

Risk factors

As filed, 20,045 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes in the risk factors described in “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021, aside from the risk factors included below:

Risks Related to Our Business and the Development and Commercialization of Our Products and Product Candidates

Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of MGC018 and our other product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other products and product candidates.

The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application (BLA) from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. For example, in November 2021, we announced the discontinuation of Cohort A of the MAHOGANY trial for margetuximab in gastric cancer, based on a number of factors, including the prioritization of our other product candidates given the competition in this indication, and the FDA’s approval of competing combination therapy with pembrolizumab. Also in July 2022, we announced the discontinuation of the Phase 2 trial of enoblituzumab in combination with either retifanlimab or tebotelimab in the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), based on an internal review of safety data. In addition, our collaborator Incyte submitted a BLA for retifanlimab in January 2021 and in July 2021, received a Complete Response Letter (CRL) from the FDA regarding its BLA. Incyte’s announcement indicated that the FDA determined that additional data are needed to demonstrate the clinical benefit of retifanlimab for the submitted indication, and that Incyte is reviewing the CRL and will discuss next steps with the FDA. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. Further, in October 2021, Incyte withdrew its European application for marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, subject our company or our collaborators to administrative or judicially imposed sanctions, including:

  • restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
  • restrictions on the products, manufacturers, manufacturing facilities or manufacturing process;
  • warning letters;
  • civil and criminal penalties;
  • injunctions;
  • suspension or withdrawal of regulatory approvals;
  • product seizures, detentions or import bans;
  • voluntary or mandatory product recalls and publicity requirements;
  • total or partial suspension of production;
  • imposition of restrictions on operations, including costly new manufacturing requirements; and
  • refusal to approve pending BLAs or supplements to approved BLAs or analogous marketing approvals outside the United States.

The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of nonclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including:

  • a product candidate may not be deemed safe or effective;
  • the results may not confirm the positive results from earlier nonclinical studies or clinical trials;
  • regulatory agencies may not find the data from nonclinical studies and clinical trials sufficient or meaningful;
  • regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or
  • regulatory agencies may change their approval policies or adopt new regulations.

Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the potential market for a product candidate, if approved.

If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue.

We, or our collaborators, are either currently enrolling patients in clinical trials or anticipate initiating, continuing, designing or supporting clinical trials for molecules that include MGC018, lorigerlimab, retifanlimab, IMGC936 and MGD024 as monotherapies or in combination with other product candidates. In addition, Incyte is currently enrolling patients in clinical trials for retifanlimab, and other collaborators outside the United States are developing our product candidates. We anticipate in the future collaborators will initiate or continue clinical trials of one or more our product candidates. The continuation, modification, or commencement of existing or new clinical trials could be substantially delayed or prevented by several factors, including:

  • further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials;
  • the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates;
  • any delay or failure in patient recruitment or enrollment in our or our collaborators’ trials for any reason, including as a result of public health crises such as the evolving COVID-19 pandemic;
  • any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;
  • inability to obtain sufficient funds required for a clinical trial;
  • clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;
  • delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials;
  • delay or failure to reach agreement on acceptable clinical trial terms or clinical trial protocols with prospective sites or CROs the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs;
  • delay or failure to obtain institutional review board (IRB) approval to conduct a clinical trial at a prospective site;
  • significant competition of product candidates that are expected to be more effective or have a more favorable safety profile; and
  • approval of potential therapies by competitors.

The progress or completion of our, or our collaborators', clinical trials have been and could also be substantially delayed or prevented by many factors, including:

  • unforeseen safety issues, including severe or unexpected adverse effects experienced by patients, including actual and possible deaths;
  • delays in expected site initiation, patient recruitment and enrollment, for any reason, including as a result of public health crises such as the evolving COVID-19 pandemic;
  • failure of patients to complete the clinical trial;
  • lack of efficacy during clinical trials;
  • termination of our clinical trials by one or more clinical trial sites;
  • inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols;
  • economic and political instability in countries where our trial sites are located, including terrorist attacks, civil unrest and actual or threatened armed conflict;
  • inability to monitor patients adequately during or after treatment by us, our collaboration partners and/or our CROs; and
  • the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.

Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including:

  • failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;
  • unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks;
  • lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and
  • upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates.

Clinical trials of our product candidates are subject to partial or full clinical holds from time to time. A clinical hold received in the midst of conducting a trial may delay the progress of a clinical trial, or may require us to modify or discontinue such trial. Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished.

The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a complete analysis of data, or in the case of interim analysis, the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval.

Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or nonclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.

We may publicly disclose top line or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial or continued progress of the study or trial. The top line or interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top line and interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In addition, the achievement of one primary endpoint for a trial does not guarantee that additional co-primary endpoints or secondary endpoints will be achieved, which may have an adverse effect on our ability to obtain or retain additional regulatory approval of MARGENZA and our product candidates in the U.S. or in other jurisdictions.

Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.

Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or after the approved product has been marketed. Ongoing or future trials of our product candidates may not support the conclusion that one or more of these product candidates have acceptable safety profiles. The results of future clinical or nonclinical trials may show undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings, risk-management measures, or potential product liability claims. For example, in July 2022 we announced the discontinuation of our Phase 2 trial of enoblituzumab in combination with either retifanlimab or tebotelimab in the treatment of patients with recurrent or metastatic SCCHN, based on an internal review of safety data.

If we or others later identify undesirable or unacceptable side effects potentially caused by such products:

  • regulatory authorities may require us to take our approved product off the market;
  • regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;
  • we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product;
  • we may be subject to limitations on how we may promote the product;
  • sales of the product may decrease significantly;
  • we may be subject to litigation or product liability claims; and
  • our reputation may suffer.

For example, the prescribing information for MARGENZA include warnings and precautions for infusion-related reactions, as well as a boxed warning related to left ventricular dysfunction and embryo-fetal toxicity. Further, based on the identification of future adverse events, we may be required to further revise the prescribing information, including MARGENZA’s boxed warning, which could negatively impact sales of MARGENZA or adversely affect MARGENZA’s acceptance in the market.

Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products.

Risks Related to Our Financial Position and Need for Additional Capital

Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises such as the COVID-19 pandemic, political crises, geopolitical events, such as the crisis in Ukraine, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance.

The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve recently raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly or more dilutive or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs.

Risks Relating to Employee Matters and Managing Growth

Our restructuring and the associated workforce reduction announced in August 2022 may not result in anticipated cost savings, could result in total costs and expenses that are greater than expected and could disrupt our business.

In August 2022, we announced a reduction in workforce by approximately 15% in connection with the restructuring of our business to prioritize and focus on our lead assets. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our operating structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our results of operation and financial condition would be adversely affected. We expect to incur additional costs as we recognize one-time employee termination-related charges. We also cannot guarantee that we will not have to undertake additional workforce reductions or restructuring activities in the future. Furthermore, our strategic restructuring plan may be disruptive to our operations. For example, our workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale. If employees who were not affected by the reduction in force seek alternate employment, this could result in us seeking contract support at unplanned additional expense or harm our productivity. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, and manufacturing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing our product candidates in the future.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-07-01 to 2022-09-30$41.7mus-gaap:Revenues
Revenue9 months2022-01-01 to 2022-09-30$78.8mus-gaap:Revenues
Cost of revenue3 months2022-07-01 to 2022-09-30$3.0mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2022-01-01 to 2022-09-30$3.2mus-gaap:CostOfGoodsAndServicesSold
Research and development3 months2022-07-01 to 2022-09-30$48.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2022-01-01 to 2022-09-30$161.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-07-01 to 2022-09-30−$25.0mus-gaap:OperatingIncomeLoss
Operating income9 months2022-01-01 to 2022-09-30−$133.4mus-gaap:OperatingIncomeLoss
Net income3 months2022-07-01 to 2022-09-30−$24.8mus-gaap:NetIncomeLoss
Net income9 months2022-01-01 to 2022-09-30−$132.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-07-01 to 2022-09-30−$0.40us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2022-01-01 to 2022-09-30−$2.16us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-07-01 to 2022-09-30−$0.40us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-01-01 to 2022-09-30−$2.16us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-07-01 to 2022-09-3061,459,831 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2022-01-01 to 2022-09-3061,390,143 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2022-01-01 to 2022-09-30−$116.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2022-01-01 to 2022-09-30$3.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-09-30$84.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-09-30$147.8mus-gaap:AssetsCurrent
Total assetsAt period end2022-09-30$195.3mus-gaap:Assets
Current liabilitiesAt period end2022-09-30$50.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-09-30$72.4mus-gaap:Liabilities
Shareholders' equityAt period end2022-09-30$123.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001125345-22-000104. Last ingested by Listed: Nov 15, 2026, 00:17 ET. Listed shows no prices and gives no investment advice.